13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001595851
Total reported value
$331.0M
$331.0M
68 檔
26.4%
In Q1 2024, Ghost Tree Capital, LLC's U.S. equity holdings reached a combined market value of $331.0M, distributed across 68 disclosed stock positions.
During Q1 2024, Ghost Tree Capital, LLC's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | XBI | Ss Spdr S&p Biotech ETF | ETF-Tech | 6.57% | — | -54.55% | |
| 2 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 4.64% | — | +27.27% | |
| 3 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 4.48% | — | +25.00% | |
| 4 | BHVN | Biohaven Ltd. | Stock-Other | 4.31% | — | +3.64% | |
| 5 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 4.17% | — | -9.09% | |
| 6 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 3.79% | — | +116.67% | |
| 7 | TGTX | Tg Therapeutics Inc | Stock-Healthcare | 3.47% | — | +230.00% | |
| 8 | VKTX | Viking Therapeutics Inc | Stock-Healthcare | 3.47% | — | — | |
| 9 | VRDN | Viridian Therapeutics Inc | Stock-Other | 3.03% | — | +108.33% | |
| 10 | TARS | Tarsus Pharmaceuticals Inc | Stock-Other | 3.02% | — | — | |
| 11 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 2.59% | — | +207.69% | |
| 12 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 2.48% | — | +118.18% | |
| 13 | IMVT | Immunovant Inc | Stock-Other | 2.46% | — | — | |
| 14 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 2.37% | — | +77.96% | |
| 15 | SVRA | Savara Inc | Stock-Other | 2.21% | — | +113.33% | |
| 16 | ACAD | Acadia Pharmaceuticals Inc | Stock-Healthcare | 2.18% | — | +750.00% | |
| 17 | APLSUSD | Apellis Pharmaceuticals Inc | Stock-Other | 2.12% | — | +30.00% | |
| 18 | ISREUR | Isoray Inc | Stock-Other | 1.98% | — | +275.00% | |
| 19 | 2655787D | Blueprint Medicines CORP | Stock-Other | 1.91% | — | — | |
| 20 | CYTK | Cytokinetics Inc | Stock-Healthcare | 1.84% | — | +5.56% | |
| 21 | ✓ | Stock-Other | 1.84% | — | +7.14% | ||
| 22 | PCVX | Vaxcyte Inc | Stock-Other | 1.80% | — | +35.71% | |
| 23 | CABA | Cabaletta Bio Inc | Stock-Other | 1.77% | — | +150.00% | |
| 24 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 1.50% | — | — | |
| 25 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 1.50% | — | +40.00% | |
| 26 | REPL | Replimune Group Inc | Stock-Other | 1.47% | — | +62.50% | |
| 27 | PHAT | Phathom Pharmaceuticals Inc | Stock-Other | 1.43% | — | +25.90% | |
| 28 | INSM | Insmed Inc | Stock-Healthcare | 1.13% | — | — | |
| 29 | TNYA | Tenaya Therapeutics Inc | Stock-Other | 1.12% | — | — | |
| 30 | SYRE | Spyre Therapeutics Inc | Stock-Other | 1.05% | — | — | |
| 31 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 0.99% | — | — | |
| 32 | ITCIEUR | Intra-cellular Therapies Inc | Stock-Other | 0.96% | — | — | |
| 33 | ✓ | Engene Holdings Inc | Stock-Other | 0.94% | — | — | |
| 34 | CGON | Cg Oncology Inc | Stock-Other | 0.91% | — | — | |
| 35 | GPCR | Structure Therapeutics Inc | Stock-Other | 0.89% | — | -50.00% | |
| 36 | ✓ | Helix Acquisition CORP Ii | Stock-Other | 0.86% | — | — | |
| 37 | COGT | Cogent Biosciences Inc | Stock-Other | 0.84% | — | +130.77% | |
| 38 | AQST | Aquestive Therapeutics Inc | Stock-Other | 0.83% | — | — | |
| 39 | DCPHEUR | Deciphera Pharmaceuticals In | Stock-Other | 0.77% | — | -21.55% | |
| 40 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 0.75% | — | -54.76% | |
| 41 | ✓ | Rapt Therapeutics Inc | Stock-Other | 0.75% | — | — | |
| 42 | GERN | Geron CORP | Stock-Other | 0.73% | — | — | |
| 43 | MRNS* | Marinus Pharmaceuticals Inc | Stock-Other | 0.71% | — | +111.11% | |
| 44 | ALT | Altimmune Inc | Stock-Other | 0.70% | — | — | |
| 45 | RGNX | Regenxbio Inc | Stock-Other | 0.70% | — | — | |
| 46 | KRYS | Krystal Biotech Inc | Stock-Healthcare | 0.69% | — | -72.00% | |
| 47 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 0.66% | — | +53.80% | |
| 48 | NTRA | Natera Inc | Stock-Healthcare | 0.63% | — | -28.57% | |
| 49 | OLMA | Olema Pharmaceuticals Inc | Stock-Other | 0.63% | — | — | |
| 50 | CRBP | Corbus Pharmaceuticals Holdi | Stock-Other | 0.62% | — | — |
According to official SEC Form 13F filings, Ghost Tree Capital, LLC reported a total U.S. public equity portfolio value of $331.0M across 68 disclosed positions in Q1 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including XBI, AXSM, SRPT) accounted for 26.4% of total reported equity market value during Q1 2024.
During Q1 2024, Ghost Tree Capital, LLC's top holdings by market value included XBI (6.6%)、AXSM (4.6%)、SRPT (4.5%). The largest single position, XBI, represented 6.6% of total portfolio value.
In Q1 2024, Ghost Tree Capital, LLC made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.